Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles.
PD-L1
biomarkers
breast cancer
breast cancer during pregnancy
early-onset breast cancer
pregnancy-related breast cancer
tumor microenvironment
tumor-infiltrating lymphocytes
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
24 07 2022
24 07 2022
Historique:
received:
15
05
2022
revised:
17
07
2022
accepted:
21
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Breast cancer during pregnancy (PrBC) is a rare tumor with only a little information on its immune landscape. Here, we sought to characterize the cellular composition of the tumor microenvironment (TME) of PrBC and identify its differences from early-onset breast cancer (EOBC) in non-pregnant women. A total of 83 PrBC and 89 EOBC were selected from our Institutional registry and subjected to tumor-infiltrating lymphocytes (TILs) profiling and immunohistochemistry for CD4, CD8, forkhead box P3 (FOXP3), and programmed death-ligand 1 (PD-L1) (clone 22C3). A significantly lower frequency of hormone receptor (HR)-positive tumors was observed in PrBC. The prevalence of low/null PD-L1 and CD8+TILs was higher in PrBC than in the controls, specifically in HR+/HER2- breast cancers. PrBC had a significantly higher risk of relapse and disease-related death, compared to EOBC. The presence of TILs and each TIL subpopulation were significantly associated with disease relapse. Moreover, the death rate was higher in PrBC with CD8+ TILs. The TME of PrBC is characterized by specific patterns of TIL subpopulations with significant biological and prognostic roles. Routine assessment of TILs and TILs subtyping in these patients would be a valid addition to the pathology report that might help identify clinically relevant subsets of women with PrBC.
Identifiants
pubmed: 35892583
pii: cells11152286
doi: 10.3390/cells11152286
pmc: PMC9332147
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Breast J. 2020 Apr;26(4):668-671
pubmed: 31448522
Lancet Oncol. 2021 Jun;22(6):753-754
pubmed: 34087122
Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:222-227
pubmed: 29728277
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32809975
Endocr Relat Cancer. 2014 Aug;21(4):545-54
pubmed: 24825746
Obstet Gynecol. 2020 Jun;135(6):1457-1478
pubmed: 32459439
Front Immunol. 2014 May 08;5:196
pubmed: 24847324
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Hum Reprod. 2019 Jan 01;34(1):25-36
pubmed: 30500923
Front Oncol. 2020 Sep 11;10:1773
pubmed: 33014874
Gynecol Oncol. 2020 Jun;157(3):799-809
pubmed: 32268951
J Immunol. 2012 Jul 15;189(2):1072-80
pubmed: 22685312
Clin Breast Cancer. 2021 Feb;21(1):e63-e73
pubmed: 32893093
Ann Oncol. 2013 Oct;24 Suppl 6:vi160-70
pubmed: 23813932
Am J Reprod Immunol. 2016 Jul;76(1):3-7
pubmed: 27293114
J Clin Invest. 2018 Oct 1;128(10):4224-4235
pubmed: 30272581
Eur J Immunol. 2020 Feb;50(2):160-169
pubmed: 31953958
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
Int J Cancer. 2018 Apr 1;142(7):1343-1354
pubmed: 29168177
Front Immunol. 2020 Oct 07;11:575197
pubmed: 33133091
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Breast. 2015 Jun;24(3):290-3
pubmed: 25702955
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Breast Cancer Res Treat. 2015 Jan;149(1):255-61
pubmed: 25504083
Anticancer Agents Med Chem. 2022;22(4):787-800
pubmed: 34229592
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Gut. 2017 May;66(5):794-801
pubmed: 26801886
Breast Cancer Res Treat. 2013 May;139(1):183-92
pubmed: 23576078
Adv Exp Med Biol. 2020;1252:87-93
pubmed: 32816266
Breast Cancer Res Treat. 2017 Jun;163(3):417-421
pubmed: 28365832
Ann Surg Oncol. 2018 Apr;25(4):937-946
pubmed: 29330719
JNCI Cancer Spectr. 2018 Dec 13;2(4):pky056
pubmed: 31360876
NPJ Breast Cancer. 2018 Aug 6;4:23
pubmed: 30109263
J Clin Oncol. 2013 Jul 10;31(20):2532-9
pubmed: 23610117
Breast Cancer Res Treat. 2021 Jul;188(2):489-500
pubmed: 34132938
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Thorac Dis. 2013 Jun;5 Suppl 1:S62-7
pubmed: 23819029
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Breast Cancer Res Treat. 2016 Nov;160(2):347-360
pubmed: 27683280
J Vis Exp. 2017 Dec 5;(130):
pubmed: 29286417
Crit Rev Oncol Hematol. 2022 Apr;172:103643
pubmed: 35217131
Histopathology. 2020 Aug;77(2):181-185
pubmed: 32056259
Cell Rep. 2020 Jun 23;31(12):107784
pubmed: 32579916
J Thorac Oncol. 2017 May;12(5):850-859
pubmed: 28257959
Horm Behav. 2012 Aug;62(3):263-71
pubmed: 22406114
Breast. 2017 Oct;35:69-77
pubmed: 28651116
Front Mol Biosci. 2022 Mar 15;9:834651
pubmed: 35372498
Ecancermedicalscience. 2020 Dec 03;14:1150
pubmed: 33574895
Histopathology. 2017 May;70(6):906-917
pubmed: 28072477
Arch Pathol Lab Med. 2021 Jul 1;145(7):887-890
pubmed: 33112946
Front Oncol. 2021 Aug 24;11:723693
pubmed: 34504801
Breast. 2016 Dec;30:215-216
pubmed: 27371969
Front Immunol. 2019 Apr 18;10:846
pubmed: 31057559
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354
J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):87-98
pubmed: 19381788
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649